Treatment-resistant depression (TRD) is a leading cause of global long-term disability.
COS’s Senior Director, Biostatistics, Lysbeth Floden and CEO Stacie Hudgens have co-authored this newly published manuscript on the Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
https://link.springer.com/article/10.1007/s40263-022-00916-2#article-info
